Donepezil (Aricept) CADASIL Study
We were honored in recruiting patients for this study. Potential patients are notified directly by us. It will be their decision to contact the study. Coordinator if they are interesting in participating in the study. No personal information was shared as we respect your privacy.The study opened January 2006
This was a randomized trial of Donepezil (Aricept, Eisai/Pfizer) in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Thank you to everyone who was screened and participated in the study. Over 255 patients were screened worldwide to participate in the study; approximately 168 patients have completed the study. We want to personally want to thank the Eisai and Parexel Companies, the doctors as well as the researchers for their dedication and hard work.
Dr. Edwin H. Kolodny, New York